Company Overview and News

 
Biotech Analysis Central Pharma News: GlaxoSmithKline Passes Along Pipeline, Pulse Impresses, Celldex's Failure

2018-04-17 seekingalpha
GlaxoSmithKline hands over rare disease unit over to Orchard Therapeutics in exchange for a 19.99% stake and board seat.
Upvote Downvote

2
Your Daily Pharma Scoop: Intercept's OCA, MediciNova In NASH, Pulse Biosciences Data

2018-04-16 seekingalpha
Intercept Pharmaceuticals (ICPT) reported clinical data from a liver biopsy-based substudy from its phase 3 POISE study. The study indicated that long-term OCA treatment in patients with PBC led to reversal or stabilization of fibrosis and cirrhosis.
Upvote Downvote

5
PLSE / Pulse Biosciences, Inc. DEF 14A

2018-04-12 sec.gov
Definitive Proxy Statement 2018  
Upvote Downvote

11
 
PLSE / Pulse Biosciences, Inc. PRE 14A

2018-03-28 sec.gov
Proxy Statement 2018  
Upvote Downvote

1
Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q4 2017 Results - Earnings Call Transcript

2018-03-17 seekingalpha
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2017 Results Earnings Conference Call March 16, 2018 4:30 PM ET
Upvote Downvote

 
BRIEF-Pulse Biosciences Inc Qtrly ‍Loss Per Share $0.53 ​

2018-03-16 reuters
* PULSE BIOSCIENCES INC - 2018 CASH USE IS CURRENTLY ANTICIPATED TO TOTAL $20 MILLION Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
Upvote Downvote

 
 
PLSE / Pulse Biosciences, Inc. 10-K (Annual Report)

2018-03-16 sec.gov
20171231 10K_Taxonomy2016 
Upvote Downvote

 
PLSE / Pulse Biosciences, Inc. / MARLETT CHRISTOPHER A - SC 13D/A (Activist Investment)

2018-02-26 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) (Amendment No. 2) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) Pulse Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74587B 10 1 (CUSIP Number) Andrew D. Hudders, Esq. Golenbock Eiseman Assor Bell & Peskoe LLP, 437 Madison Avenue, New York, New York 10022 (212-907-7300) (Name, Address and Telephon
Upvote Downvote

1
PLSE / Pulse Biosciences, Inc. / MARLETT CHRISTOPHER A - SC 13D/A (Activist Investment)

2018-02-26 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) (Amendment No. 2) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) Pulse Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74587B 10 1 (CUSIP Number) Andrew D. Hudders, Esq. Golenbock Eiseman Assor Bell & Peskoe LLP, 437 Madison Avenue, New York, New York 10022 (212-907-7300) (Name, Address and Telephon
Upvote Downvote

 
PLSE / Pulse Biosciences, Inc. / Newbem Corp. - SC 13G (Passive Investment)

2018-02-09 sec.gov
SC 13G     SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A )*     Pulse Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74587B 10 1 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   ☐ Rule 13d-1(b)   ☐ Rule 13d-1(c)  
Upvote Downvote

PLSE: Pulse Biosciences Analysis and Research Report

2018-02-19 - Asif

Pulse Biosciences is a clinical-stage medical technology company developing a non-thermal tissue treatment platform technology based upon its proprietary Nano-Pulse Stimulation (“NPS”) technology and pursuing applications in oncology, dermatology, general tissue treatment and veterinary medicine. NPS is a novel patented technology which leverages nano-second duration energy pulses that have demonstrated effective local tumor control and the initiation of an adaptive immune response in pre-clinical studies. Pulse Biosciences is pursuing a number of clinical applications for NPS, including oncology, dermatology, aesthetics and other minimally invasive applications where the company believe NPS has the potential to compare favorably with current therapies and treatments. Pulse Biosciences is currently conducting research and development activities in pursuit of commercial applications for its NPS technology, but Pulse Biosciences has not yet commercialized or recognized revenue from its t...

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 74587B101